Respiratory syncytial virus, or RSV, is often overlooked compared to other viruses like the one that causes COVID-19 and the flu.
While it causes cold-like respiratory symptoms in most people, an infection can be dangerous for certain populations. That’s why scientists have been working hard on a treatment that can protect those who are vulnerable.
RSV tends to be most severe in infants and older adults, potentially leading to hospitalization or even death, according to the Centers for Disease Control and Prevention. In fact, the CDC estimates that between 6,000 and 10,000 at-risk adults die of RSV each year, and 58,000 to 80,000 children are hospitalized because of the virus.